John J. Kuch
Net Worth
Last updated:
What is John J. Kuch net worth?
The estimated net worth of Mr. John J. Kuch is at least $8,267,351 as of 11 Mar 2024. He owns shares worth $937,082 as insider, has earned $311,109 from insider trading and has received compensation worth at least $7,019,160 in Xencor, Inc..
What is the salary of John J. Kuch?
Mr. John J. Kuch salary is $584,930 per year as Senior Vice President & Chief Financial Officer in Xencor, Inc..
How old is John J. Kuch?
Mr. John J. Kuch is 66 years old, born in 1959.
What stocks does John J. Kuch currently own?
As insider, Mr. John J. Kuch owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Xencor, Inc. (XNCR) | Senior Vice President & Chief Financial Officer | 121,070 | $7.74 | $937,082 |
What does Xencor, Inc. do?
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
John J. Kuch insider trading
Xencor, Inc.
Mr. John J. Kuch has made 15 insider trades between 2013-2024, according to the Form 4 filled with the SEC. Most recently he sold 849 units of XNCR stock worth $19,953 on 11 Mar 2024.
The largest trade he's ever made was exercising 50,000 units of XNCR stock on 24 Jun 2016. As of 11 Mar 2024 he still owns at least 121,070 units of XNCR stock.
Xencor key executives
Xencor, Inc. executives and other stock owners filed with the SEC:
- Dr. Allen S. Yang M.D., Ph.D. (57) Senior Vice President & Chief Medical Officer
- Dr. Bassil I. Dahiyat Ph.D. (55) Co-Founder, Chief Executive Officer, Pres & Director
- Dr. John R. Desjarlais (61) Senior Vice President of Research & Chief Scientific Officer
- Mr. John J. Kuch (66) Senior Vice President & Chief Financial Officer
- Ms. Celia E. Eckert J.D. (53) Vice President, Gen. Counsel & Corporation Sec.